Lexeo Therapeutics, Inc. 8-K

What Happened

• Lexeo Therapeutics filed an 8-K on January 27, 2026 announcing senior management changes. The Board appointed Jose Manuel Otero, Ph.D., the company’s Chief Technical Officer, to serve as Chief Operating Officer effective January 2, 2026. The Board also appointed Narinder P. Bhalla, M.D., to serve as Chief Medical Officer effective January 20, 2026.
• Eric Adler, M.D., the company’s Head of Research, will no longer be an executive officer of Lexeo effective January 27, 2026 as he assumes the role of President and Chief Executive Officer of Myoventive, Inc., a cardiac precision medicines company co-founded in June 2025. Dr. Adler will remain a senior clinical and scientific advisor to Lexeo.

Key Details

• Appointment effective dates: Jose M. Otero as COO — January 2, 2026; Narinder P. Bhalla as CMO — January 20, 2026; Dr. Adler ceases to be an executive officer — January 27, 2026.
• New base salary for Dr. Otero approved at $510,000 per year; he continues under his existing compensation arrangements otherwise.
• Dr. Otero was promoted internally from CTO; he has signed Lexeo’s standard indemnification agreement for officers and directors.
• Filings state there are no arrangements or understandings related to Dr. Otero’s appointment, no family relationships with other executives or directors, and no reportable related-party transactions under Item 404(a).

Why It Matters

• These filings formally update Lexeo’s senior leadership and compensation: an internal promotion to COO and a new Chief Medical Officer change who will oversee clinical/medical functions. The former Head of Research transitions off the company’s executive roster but will continue advising Lexeo while leading a spin-out company.
• For investors, the filing signals leadership continuity (internal promotion) and an active reshaping of the clinical and operational team; it also discloses a specific compensation change ($510,000 base salary) for the new COO.